| Xu, Rui-hua |
NCT03837808: Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 384 | RoW | Nimotuzumab, Cisplatin | Sun Yat-sen University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangdong Provincial People's Hospital, First Affiliated Hospital, Sun Yat-Sen University | Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Nasopharyngeal Diseases, Head and Neck Neoplasm | 02/24 | 02/24 | | |
NCT06497985: Phase III Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients |
|
|
| Not yet recruiting | 3 | 430 | NA | Tucidinostat, Chidamide, Sintilimab, Bevacizumab, Fruquintinib | Chipscreen Biosciences, Ltd. | Colorectal Cancer | 05/28 | 09/28 | | |
NCT03840421: GP vs PF as Induction Chemotherapy Combined With CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma |
|
|
| Active, not recruiting | 3 | 468 | RoW | gemcitabine and cisplatin, gemcitabine and cisplatin (GP), cisplatin and fluorouracil, cisplatin and fluorouracil (PF), IMRT, cisplatin, cisplatin（DDP） | Sun Yat-sen University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangdong Provincial People's Hospital, First Affiliated Hospital, Sun Yat-Sen University | Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Nasopharyngeal Diseases, Head and Neck Neoplasm | 08/26 | 12/28 | | |
NCT03671252: Prospectively Randomized Control Clinical Trial of FOLFOXIRI Preoperative Chemotherapy Alone on Rectal Cancer in Local Advance Comparing to Oral Capecitabine Combined With Long-term Radiation |
|
|
| Recruiting | 3 | 776 | RoW | FOLFOXIRI, XELOX, Chemoradiotherapy, TME operation, efficacy evaluation | Sun Yat-sen University | Rectal Cancer | 09/25 | 09/28 | | |
NCT05737563: PD-1 Antibody Combined With mXELIRI Versus mXELIRI in the Second-line Setting for ESCC |
|
|
| Recruiting | 3 | 380 | RoW | PD-1 Inhibitors, Irinotecan, Capecitabine tablets | Sun Yat-sen University, Shanghai Junshi Bioscience Co., Ltd., Jiangsu HengRui Medicine Co., Ltd. | Esophageal Squamous Cell Carcinoma Abdominal Stage 0 | 02/26 | 02/26 | | |
NCT04250948: Efficacy of Perioperative Chemotherapy Plus PD-1 Antibody in the Locally Advanced Gastric Cancer |
|
|
| Active, not recruiting | 2 | 108 | RoW | JS001, PD-1 antibody, Oxaliplatin, S1, Capecitabine, XELODA | Sun Yat-sen University, Shanghai Junshi Bioscience Co., Ltd. | Gastric Cancer, Locally Advanced Solid Tumor | 06/22 | 10/24 | | |
NCT05163483: Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer |
|
|
| Recruiting | 2 | 87 | RoW | Tucidinostat (chidamide), PD-1 inhibitor (Toripalimab), Bevacizumab, Tucidinostat (chidamide) JS001 | Ruihua Xu | Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma | 12/23 | 12/25 | | |
NCT03810339: Toripalimab as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors |
|
|
| Recruiting | 2 | 35 | RoW | Toripalimab | Sun Yat-sen University | Solid Tumor, Advanced Cancer | 01/24 | 01/24 | | |
NCT06396637: PD-1 Antibody and Sapropterin Dihydrochloride in Patients With PDAC |
|
|
| Recruiting | 2 | 20 | RoW | Sapropterin Dihydrochloride, PD-1 Antibody | Sun Yat-sen University, Innovent Biologics (Suzhou) Co. Ltd. | Pancreatic Adenocarcinoma Metastatic | 04/25 | 04/25 | | |
NCT05173246: JS001 Combined With TP as First-line Treatment for Unresectable or Advanced Small Cell Esophageal Carcinoma |
|
|
| Recruiting | 2 | 43 | RoW | JS001, recombinant humanized anti-PD-1 monoclonal antibody for injection, nab-paclitaxel, Paclitaxel for injection (Albumin Bound), Cisplatin, Cisplatin for injection, Carboplatin, Carboplatin for injection | Sun Yat-sen University, Shanghai Junshi Bioscience Co., Ltd., CSPC Ouyi Pharmaceutical Co., Ltd. | Esophageal Small Cell Carcinoma | 11/24 | 11/25 | | |
NCT05576961: Safety and Efficacy of RX-af01 Combined With PD-1 Antibody |
|
|
| Recruiting | 1/2 | 60 | RoW | RX-af01, Toripalimab, Mixed bacteria, High dose RX-af01 | Sun Yat-sen University | Solid Tumor, Immune Checkpoint Inhibitor, Intestinal Flora | 12/24 | 12/24 | | |
| Zhang, Xiaoshi |
NCT05690035: Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer |
|
|
| Withdrawn | 2 | 12 | RoW | Tislelizumab & Fruquintinib | Sun Yat-sen University, Hutchmed, BeiGene | Metastatic Colorectal Cancer, mCRC | 07/25 | 07/25 | | |
NCT05148533: A Study of Single Drug TJ011133 and Toripalimab Combine Treatment for Advanced Solid Tumor |
|
|
| Terminated | 1/2 | 7 | RoW | TJ1133 Injection | TJ Biopharma Co., Ltd. | Advanced Solid Tumor | 02/23 | 02/23 | | |
NCT06214156: A Clinical Study of T3011 in Subjects With Advanced Melanoma |
|
|
| Recruiting | 1/2 | 42 | RoW | T3011 | Shanghai Pharmaceuticals Holding Co., Ltd | Advanced Melanoma | 09/24 | 07/25 | | |
TAL-T, NCT06302062: Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors |
|
|
| Recruiting | 1 | 23 | RoW | Tumor Associated Lymph node T cell, TAL-T cells, FIT003, TAL-T, cyclophosphamide, IL-2, Cellular interleukin 2, interleukin-2, Serplulimab Injection, PD1 monoclonal antibody, PD1 | Guangzhou FineImmune Biotechnology Co., LTD. | Advanced Solid Tumor, Tumor Associated Lymph Node T Cell, Immunotherapy | 12/25 | 06/26 | | |
NCT06536400: Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation |
|
|
| Recruiting | 1 | 316 | RoW | HSK42360 | Haisco Pharmaceutical Group Co., Ltd. | Solid Tumors | 08/26 | 07/27 | | |
NCT03891706: Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid Tumors |
|
|
| Recruiting | 1 | 30 | RoW | tumor-specific TCR-T cells, TCR-T cells, FIT-001, Interleukin-2, IL-2 | Guangzhou FineImmune Biotechnology Co., LTD., Sun Yat-sen University | Solid Tumor | 10/25 | 12/25 | | |
NCT04936178: A Study of NB003 in Patients With Advanced Malignancies |
|
|
| Recruiting | 1 | 258 | Europe, US, RoW | NB003 tablets | Ningbo Newbay Technology Development Co., Ltd | Advanced Solid Tumor | 07/25 | 12/25 | | |
